Back to search results

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

Abroad (travel likely)RecruitingPHASE2

Conditions

Sickle Cell Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Centre Hospitalier Intercommunal Créteil, Créteil, France

    Contact: Study coordinator (Cecile Arnaud, MD)
    Contact: Principal Investigator (Cecile Arnaud, MD)

  • GHEF- Site de Marne-la-Vallée, Jossigny, France

    Contact: Study coordinator (Kokou AGBO KPATI) · kagbokpati@ghef.fr

  • Hôpital Bicêtre, Le Kremlin-Bicêtre, France

    Contact: Study coordinator (Corinne Guitton, MD)
    Contact: Principal Investigator (Corinne Guitton, MD)

  • Institut d'Hématologie et d'oncologie pédiatrique - IHOPe, Lyon, France

  • Hôpital Necker-Enfants malades, Paris, France

    Contact: Study coordinator (Josephine Brice, MD)
    Contact: Principal Investigator (Josephine Brice, MD)

  • Centre hospitalier de Cayenne, Cayenne, French Guiana

    Contact: Study coordinator (Narcisse Elenga, MD, PhD)
    Contact: Principal Investigator (Narcisse Elenga, MD, PhD)
Study leads

  • Josephine Brice, MD

    Principal Investigator

    Hôpital Necker-Enfants Malades

View source on ClinicalTrials.gov(opens in a new tab)